Tests whether an amylin-like drug triggers migraine attacks in people with migraine
Tests whether pramlintide, an amylin-like drug, induces migraine attacks in adults with migraine.
Plain-language title generated from the registry record
Registry title: Amylin-Induced Migraine Attacks Without Aura
Key facts
- Where
- Glostrup Municipality, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07340788, who can take part
Where in Denmark
- Rigshospitalet GlostrupGlostrup Municipality, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Danish Headache Center
- Trial code
- NCT07340788
- Record updated
- 14 January 2026
- Original description
Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.Read full original descriptionShow less
Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial
Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.
Inclusion: Age 18 to 65 years of age upon entry into screening; A body weight of 50 to 100 kg; History of migraine without aura for ≥12 months and in accordance with ICHD-3; Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening; Provision of informed consent prior to initiation of any study-specific activities/procedures.
Exclusion: Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day; Daily use of any medication other than contraceptives; Intake of any medication other than contraceptives within 48 hours of infusion start; Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache; Any history of moderate to severe traumatic brain injury; Any history of cardiovascular disease, including cerebrovascular diseases; Any history of pulmonary disease; Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results; Cardiovascular disease of any kind, including cerebrovascular diseases; The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior; Female subjects of childbearing potential with a positive pregnancy test during any study visit; Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg); Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results; Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start; Headache of any intensity within 48 hours of infusion start; Migraine attack within 48 hours of infusion start; Aura within 48 hours of infusion start.